Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma Guide

Delpharm Consultants Pty Limited

Delpharm Consultants is one of Australia's leading independent consultancies focusing on pharmaceutical development and related regulatory issues.

Since 1994 we have been providing high quality consultancy and impartial advice to members of the pharmaceutical and biotechnology industries, including advice in areas such as:


Clinical Trial Design and Management;
Regulatory Management Services;
Commercialisation;
GCP Compliance Audits; and
Data Reduction and Final Reports.

Our experienced consultants have held senior positions in the pharmaceutical industry and have considerable expertise in the areas of contract and academic research.

Address: Suites 211 & 212, 5 Alexander St
State: NSW
Suburb: Crows Nest
Postcode: 2065

Phone: (02) 9966-8622
Fax: (02) 9966-9244
Email: delphar@bigpond.net.au
Web address: www.delpharm.com.au

Special Report
PBAC March outcomes in full
In a meeting that saw 22 major medicines submissions, positive and negative results were equally mixed with nine of each plus two deferrals and two no results because of a lack of data from the TGA.
Pipeline Monitor
FDA shoots down Olumiant
The FDA has surprised by rejecting Lilly and Incyte's oral rheumatoid arthritis drug Olumiant, diverging from the EU's approval of the drug in February.
Approvals Action
Keytruda wins another indication
The TGA has revealed the granting of a new indication to MSD's blockbuster cancer drug Keytruda and CSL's new product Afstyla has been approved for treating haemophilia A.